Corbus announced today that the Poster [#296] "Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate," has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center. For details: https://bit.ly/3wP0oLn #ASCO24
Corbus Pharmaceuticals’ Post
More Relevant Posts
-
Clinical Science Executive | Drug Developer | Regulatory Strategist | Author & Speaker | 2022 Woman Worth Watching® in STEM | 2023 Top 25 Healthcare Technology Leaders of Virginia | 2023 TOPRA Award Winner, Education
Got some interesting data related to targeted drugs in cancer? Or maybe you have an idea for a review paper on this topic? The Cancers MDPI special issue "Research on Targeted Drugs in Cancer" is now open for submissions! Learn more here: https://lnkd.in/g-ii5VND #callforpapers #targetedtherapy #oncology #cancer #clinicaltrials #regulatory #drugdevelopment
To view or add a comment, sign in
-
We are pleased to report Q3 earnings today. This quarter has been exciting for Calidi Biotherapeutics, highlighted by: - New data on the first patient dosing in our CLD-101 recurrent high grade glioma trial at City of Hope. - New preclinical data on CLD-201 presented at Society for Immunotherapy of Cancer (SITC) #sitc23. - The introduction of new members to our Board of Directors and Executive Team. We are encouraged by our continued clinical progress and are looking forward to closing 2023 out strong. Read more here: https://lnkd.in/dam44dxu #calidi #stemcells #q3earnings #clinicaltrials #curecancer
To view or add a comment, sign in
-
-
Exciting Update: A multitude of new #Oncology #Drugs are currently in the #Pipeline, promising advancements in cancer treatment. Challenge Ahead: #Research Sites, already grappling with complexity and volume, face the risk of becoming even more overwhelmed. The solution? Embracing new #technologies to streamline processes! Our Solutions: - Inteliquet, an IQVIA business streamlines Trial Matching & Screening, ensuring patients are matched with the most suitable trials. - Our IQVIA #EMRtoEDC Solution streamlines data collection, making it easier for research sites to manage and analyze data. Interested in learning more about how we can assist? Or perhaps you’d like to connect with our teams at the upcoming #ASCO conference? Don’t hesitate to reach out. We’re here to help navigate the future of oncology research together. Mui Van Zandt Alan Frederickson PMP® Sneha Kishnani, PMP James Coutcher John Pappa Kelly Smith Sabrina Cheema Anastasia Pargulski, MPH
🔔Now Live: IQVIA Institute's The Global Oncology Trends 2024 report. This innovative, evidence-based report features: ➡️Profiles of the latest available data on cancer incidence and survival. ➡️The current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. ➡️Metrics of clinical development productivity. ➡️Trends in the use of novel mechanisms in specific cancer types. ➡️Expectations for how spending dynamics will play out over the next five years. Download the report here: https://lnkd.in/ez8wrzdv #Oncology #CancerResearch #LifeSciences #GlobalHealth
To view or add a comment, sign in
-
-
Check out the latest trends in Oncology with the new IQVIA Institute report!
🔔Now Live: IQVIA Institute's The Global Oncology Trends 2024 report. This innovative, evidence-based report features: ➡️Profiles of the latest available data on cancer incidence and survival. ➡️The current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. ➡️Metrics of clinical development productivity. ➡️Trends in the use of novel mechanisms in specific cancer types. ➡️Expectations for how spending dynamics will play out over the next five years. Download the report here: https://lnkd.in/ez8wrzdv #Oncology #CancerResearch #LifeSciences #GlobalHealth
To view or add a comment, sign in
-
-
Just published! IQVIA Institute's The Global Oncology Trends 2024 report, download from link below.
🔔Now Live: IQVIA Institute's The Global Oncology Trends 2024 report. This innovative, evidence-based report features: ➡️Profiles of the latest available data on cancer incidence and survival. ➡️The current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. ➡️Metrics of clinical development productivity. ➡️Trends in the use of novel mechanisms in specific cancer types. ➡️Expectations for how spending dynamics will play out over the next five years. Download the report here: https://lnkd.in/ez8wrzdv #Oncology #CancerResearch #LifeSciences #GlobalHealth
To view or add a comment, sign in
-
-
Exciting news for the healthcare community! The IQVIA Institute has released its latest report, "Global Oncology Trends 2024," providing valuable insights into cancer research and treatment. Key highlights include: Profiles of the latest data on cancer incidence and survival rates Updates on research and development in oncology, including key mechanisms and targets Metrics on clinical development productivity Trends in the use of novel mechanisms for specific cancer types Spending dynamics expected over the next five years #Oncology #CancerResearch #LifeSciences #GlobalHealth #Oncology #CancerResearch #LifeSciences #GlobalHealth
🔔Now Live: IQVIA Institute's The Global Oncology Trends 2024 report. This innovative, evidence-based report features: ➡️Profiles of the latest available data on cancer incidence and survival. ➡️The current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. ➡️Metrics of clinical development productivity. ➡️Trends in the use of novel mechanisms in specific cancer types. ➡️Expectations for how spending dynamics will play out over the next five years. Download the report here: https://lnkd.in/ez8wrzdv #Oncology #CancerResearch #LifeSciences #GlobalHealth
To view or add a comment, sign in
-
-
Q&A: The potential of immuno-oncology - a view from the R&D department Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing in... https://lnkd.in/eHFZyizw #BioTech #science
To view or add a comment, sign in
-
Shout out to Drs. Nelson and Subbiah for their astutely written reply to the Conley et al. editorial on the “adscopal effect” in the high-impact journal, Molecular Cancer Therapeutics. Read it here: https://bit.ly/3SqI55Y An “abscopal effect” classically refers to the regression of distant tumors outside the treatment field of radiation therapy. By contrast, the “adscopal effect," a term coined by Conley et al. describes the shrinkage of distant, noninjected visceral lesions mediated by the oncolytic adenovirus, AdAPT-001. As Nelson and Subbiah point out, what differentiates oncolytic adenoviruses like AdAPT-001 from other oncolytic viruses is that they “piggyback” on lymphocytes and erythrocytes, which are thought to shield them from the presence of neutralizing antibodies so that these adenoviruses reach and transduce non-injected tumors. Our expectation is that if AdAPT-001 continues to make waves in hard-to-treat tumors like sarcomas, the novel term “adscopal effect” will become conventionalized and formally enter the clinical lexicon.
In a just-published editorial from the impactful journal, Molecular Cancer Therapeutics, Anthony Conley et al. define a new term, “adscopal effect,” that refers to the immune-mediated action-at-a-distance activity with the EpicentRx oncolytic adenovirus, AdAPT-001, that expresses a TGF-β trap. Read here: https://bit.ly/3vZx0B7
To view or add a comment, sign in
-
-
Yesterday we have just posted the Global Oncology Trends 2024 Report oncology trends report. Follow the link below and be informed about the current situation and next year dynamics. #datascience #clinicalresearch #oncology
🔔Now Live: IQVIA Institute's The Global Oncology Trends 2024 report. This innovative, evidence-based report features: ➡️Profiles of the latest available data on cancer incidence and survival. ➡️The current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. ➡️Metrics of clinical development productivity. ➡️Trends in the use of novel mechanisms in specific cancer types. ➡️Expectations for how spending dynamics will play out over the next five years. Download the report here: https://lnkd.in/ez8wrzdv #Oncology #CancerResearch #LifeSciences #GlobalHealth
To view or add a comment, sign in
-